Post Reply
681-700 of 1176
Coming q, higher rev n profit....
y2jchris ( Date: 03-Mar-2021 13:02) Posted:
Extra top-up comes from helping Singapore with vaccine adminstrative?
But the good part is... the + gonna spread throughout few quarters. Free money to them.
Laihuat68 ( Date: 03-Mar-2021 09:35) Posted:
| Better prospects expected for Raffles Medical Group in FY2021: analysts
amala Balakrishner Published on Tue, Mar 2, 2021 / 11:38 PM GMT+8 / Updated 1 hour ago
Analysts are upbeat on the prospects of healthcare services provider Raffles Medical Group for they expect FY2021 ending in December to bring it ?some normalisation?.
In its recent results for FY2020, the group reported earnings of $65.9 million, up 9.3% y-o-y thanks to its provision of new services such as the Covid-19 Polymerase Chain Reaction (PCR) and serology testing.
In this time, its revenue was up 8.8% on year to $568.2 million, following an 18.4% growth in the performance of its healthcare services segment, possibly due to Covid-19 related works.
This was a ?positive surprise? to CGS-CIMB analyst Cezzanne See who had expected Raffles Medical?s income to come in it around $500 million in FY2020.
Maybank Kim Eng analyst Lai Gene Lih was similarly surprised, particularly by the group?s 2H2020 PATMI (profit after taxes minus interests) which had risen 50% on year to hit $46.8 million.
?This was ahead of our and street?s expectations,? she says in a research note. Lai attributes this to: activities related to the Covid-19 battle and the government?s wage support.
Looking ahead, the group?s ?management expects normalisation of most of Raffles Medical Group?s operations within FY2021, including the return of some foreign patients,? Lai notes in a research note.
She is expecting these foreign patients to return, especially to the group?s hospitals in China, since the Covid-19 vaccination has been taking place globally.
PhillipCapital analyst Tay Wee Kuang reckons this will be supported by the completion of the upgrading works at RaffleshospitalBeijing such that it can now support inpatient services and offer minimally-invasive surgeries.
?This is expected to boost profitability,? he stresses in a research note.
Aside from this, Tay says that the opening of RafflesHospitalShanghai by mid-FY2021 is something the group can look forward to.
?Being a more cosmopolitan city with a bigger expat presence, demand for private healthcare in Shanghai is expected to be higher,? he mills.
Given the group?s existing presence in Shanghai, he reckons that its EBITDA (earnings before interest, taxes, depreciation and ammortisation) losses will be less than that incurred in the setting up of its RafflesHospitalChongqing.
RafflesHospitalChongqing is still yielding EBITDA losses of below $10 million despite having an increase in patient loads from FY2019.
However, Tay believes it remains on track to break even in FY2021 ?as China has contained Covid-19 swiftly?.
Meanwhile, its operations back home has already seen an improvement in 2H2020, with local patient numbers returning to pre-pandemic levels.
CGS-CIMB?s See is positive that this will continue as the group continues its support of the government?s Covid-19 efforts and national vaccination drive through the four centres it has operations in.
Against this backdrop, she is lifting her forecast for Raffles Medical?s revenue for FY2021-FY2022 ?to account for the continued Covid-19 work [and an] increase [in] tax expenses?.
Tay conversely, has lowered his earnings forecast for FY2021 by 10%, despite his prediction of the year bringing healthy revenue.
This is to factor in RafflesHospitalShanghai?s gestation in 1H2021 as well as the higher expenses related to an expanded business, he explains.
These are also areas of concern to analysts at OCBC Investment Research. ?Weaker than expected ramp up at its new projects in China, costs containment issues impacting overall margins,? are other investment risks they foresee.
Still, three out of four of the analysts have posted ?buy? or ?accumulate? calls on Raffles Medical Group.
PhillipCapital?s Tay has a target price of $1.18, while analysts at OCBC Investment Research have a $1.15 target. Maybank Kim Eng?s Lai?s target is $1.10.
See has conversely maintained her ?hold? call at a higher target price of $1.10. This is up from her previous 96 cent call and is believed to give the counter a 7.9% upside from its $1.02 price on Feb 22.
Shares in Raffles Medical Group closed up 20 cents or 1.18% at $1.12 on Mar 2.
|
|
|
|
waiting fr it to pierce thru 1.10....
opening of shanghai hosp vry soon in 2nd half tis yr....my pick fr 2021.....dyodd....
Fri married deal 377,200 share at 1.068....am following to accumulate...div coming vry soon....
1.12 clear.. 👍
halleluyah ( Date: 03-Mar-2021 09:37) Posted:
|
Extra top-up comes from helping Singapore with vaccine adminstrative?
But the good part is... the + gonna spread throughout few quarters. Free money to them.
Laihuat68 ( Date: 03-Mar-2021 09:35) Posted:
| Better prospects expected for Raffles Medical Group in FY2021: analysts
amala Balakrishner Published on Tue, Mar 2, 2021 / 11:38 PM GMT+8 / Updated 1 hour ago
Analysts are upbeat on the prospects of healthcare services provider Raffles Medical Group for they expect FY2021 ending in December to bring it ?some normalisation?.
In its recent results for FY2020, the group reported earnings of $65.9 million, up 9.3% y-o-y thanks to its provision of new services such as the Covid-19 Polymerase Chain Reaction (PCR) and serology testing.
In this time, its revenue was up 8.8% on year to $568.2 million, following an 18.4% growth in the performance of its healthcare services segment, possibly due to Covid-19 related works.
This was a ?positive surprise? to CGS-CIMB analyst Cezzanne See who had expected Raffles Medical?s income to come in it around $500 million in FY2020.
Maybank Kim Eng analyst Lai Gene Lih was similarly surprised, particularly by the group?s 2H2020 PATMI (profit after taxes minus interests) which had risen 50% on year to hit $46.8 million.
?This was ahead of our and street?s expectations,? she says in a research note. Lai attributes this to: activities related to the Covid-19 battle and the government?s wage support.
Looking ahead, the group?s ?management expects normalisation of most of Raffles Medical Group?s operations within FY2021, including the return of some foreign patients,? Lai notes in a research note.
She is expecting these foreign patients to return, especially to the group?s hospitals in China, since the Covid-19 vaccination has been taking place globally.
PhillipCapital analyst Tay Wee Kuang reckons this will be supported by the completion of the upgrading works at RaffleshospitalBeijing such that it can now support inpatient services and offer minimally-invasive surgeries.
?This is expected to boost profitability,? he stresses in a research note.
Aside from this, Tay says that the opening of RafflesHospitalShanghai by mid-FY2021 is something the group can look forward to.
?Being a more cosmopolitan city with a bigger expat presence, demand for private healthcare in Shanghai is expected to be higher,? he mills.
Given the group?s existing presence in Shanghai, he reckons that its EBITDA (earnings before interest, taxes, depreciation and ammortisation) losses will be less than that incurred in the setting up of its RafflesHospitalChongqing.
RafflesHospitalChongqing is still yielding EBITDA losses of below $10 million despite having an increase in patient loads from FY2019.
However, Tay believes it remains on track to break even in FY2021 ?as China has contained Covid-19 swiftly?.
Meanwhile, its operations back home has already seen an improvement in 2H2020, with local patient numbers returning to pre-pandemic levels.
CGS-CIMB?s See is positive that this will continue as the group continues its support of the government?s Covid-19 efforts and national vaccination drive through the four centres it has operations in.
Against this backdrop, she is lifting her forecast for Raffles Medical?s revenue for FY2021-FY2022 ?to account for the continued Covid-19 work [and an] increase [in] tax expenses?.
Tay conversely, has lowered his earnings forecast for FY2021 by 10%, despite his prediction of the year bringing healthy revenue.
This is to factor in RafflesHospitalShanghai?s gestation in 1H2021 as well as the higher expenses related to an expanded business, he explains.
These are also areas of concern to analysts at OCBC Investment Research. ?Weaker than expected ramp up at its new projects in China, costs containment issues impacting overall margins,? are other investment risks they foresee.
Still, three out of four of the analysts have posted ?buy? or ?accumulate? calls on Raffles Medical Group.
PhillipCapital?s Tay has a target price of $1.18, while analysts at OCBC Investment Research have a $1.15 target. Maybank Kim Eng?s Lai?s target is $1.10.
See has conversely maintained her ?hold? call at a higher target price of $1.10. This is up from her previous 96 cent call and is believed to give the counter a 7.9% upside from its $1.02 price on Feb 22.
Shares in Raffles Medical Group closed up 20 cents or 1.18% at $1.12 on Mar 2.
|
|
1.12 resistent....
Better prospects expected for Raffles Medical Group in FY2021: analysts
amala Balakrishner Published on Tue, Mar 2, 2021 / 11:38 PM GMT+8 / Updated 1 hour ago
Analysts are upbeat on the prospects of healthcare services provider Raffles Medical Group for they expect FY2021 ending in December to bring it ?some normalisation?.
In its recent results for FY2020, the group reported earnings of $65.9 million, up 9.3% y-o-y thanks to its provision of new services such as the Covid-19 Polymerase Chain Reaction (PCR) and serology testing.
In this time, its revenue was up 8.8% on year to $568.2 million, following an 18.4% growth in the performance of its healthcare services segment, possibly due to Covid-19 related works.
This was a ?positive surprise? to CGS-CIMB analyst Cezzanne See who had expected Raffles Medical?s income to come in it around $500 million in FY2020.
Maybank Kim Eng analyst Lai Gene Lih was similarly surprised, particularly by the group?s 2H2020 PATMI (profit after taxes minus interests) which had risen 50% on year to hit $46.8 million.
?This was ahead of our and street?s expectations,? she says in a research note. Lai attributes this to: activities related to the Covid-19 battle and the government?s wage support.
Looking ahead, the group?s ?management expects normalisation of most of Raffles Medical Group?s operations within FY2021, including the return of some foreign patients,? Lai notes in a research note.
She is expecting these foreign patients to return, especially to the group?s hospitals in China, since the Covid-19 vaccination has been taking place globally.
PhillipCapital analyst Tay Wee Kuang reckons this will be supported by the completion of the upgrading works at RaffleshospitalBeijing such that it can now support inpatient services and offer minimally-invasive surgeries.
?This is expected to boost profitability,? he stresses in a research note.
Aside from this, Tay says that the opening of RafflesHospitalShanghai by mid-FY2021 is something the group can look forward to.
?Being a more cosmopolitan city with a bigger expat presence, demand for private healthcare in Shanghai is expected to be higher,? he mills.
Given the group?s existing presence in Shanghai, he reckons that its EBITDA (earnings before interest, taxes, depreciation and ammortisation) losses will be less than that incurred in the setting up of its RafflesHospitalChongqing.
RafflesHospitalChongqing is still yielding EBITDA losses of below $10 million despite having an increase in patient loads from FY2019.
However, Tay believes it remains on track to break even in FY2021 ?as China has contained Covid-19 swiftly?.
Meanwhile, its operations back home has already seen an improvement in 2H2020, with local patient numbers returning to pre-pandemic levels.
CGS-CIMB?s See is positive that this will continue as the group continues its support of the government?s Covid-19 efforts and national vaccination drive through the four centres it has operations in.
Against this backdrop, she is lifting her forecast for Raffles Medical?s revenue for FY2021-FY2022 ?to account for the continued Covid-19 work [and an] increase [in] tax expenses?.
Tay conversely, has lowered his earnings forecast for FY2021 by 10%, despite his prediction of the year bringing healthy revenue.
This is to factor in RafflesHospitalShanghai?s gestation in 1H2021 as well as the higher expenses related to an expanded business, he explains.
These are also areas of concern to analysts at OCBC Investment Research. ?Weaker than expected ramp up at its new projects in China, costs containment issues impacting overall margins,? are other investment risks they foresee.
Still, three out of four of the analysts have posted ?buy? or ?accumulate? calls on Raffles Medical Group.
PhillipCapital?s Tay has a target price of $1.18, while analysts at OCBC Investment Research have a $1.15 target. Maybank Kim Eng?s Lai?s target is $1.10.
See has conversely maintained her ?hold? call at a higher target price of $1.10. This is up from her previous 96 cent call and is believed to give the counter a 7.9% upside from its $1.02 price on Feb 22.
Shares in Raffles Medical Group closed up 20 cents or 1.18% at $1.12 on Mar 2.
Look good... 👍 🤔
one way up...strong accumulation....growth stock....
y2jchris ( Date: 01-Mar-2021 12:24) Posted:
Any bros or sis here know how much garmen is paying RM to oversee all the vaccine injection?
Is it charged per head?
Assuming now Singapore is 5.704 million now
Assuming now Singapore is 50% of the Singaporean volunteer to take vaccine.. that' s 2.8m.. imagine 1 injection set cost about $50 bucks.... 150million revenue spread across 2021 beyond.
I am not encouraged to buy or sell. But just 2 cents here. Look at the function of the base number...
Even the CEO and director acquire more shares.. this pie.. seems to be solo eater RM.
|
|
1.20 is on the way.....
Any bros or sis here know how much garmen is paying RM to oversee all the vaccine injection?
Is it charged per head?
Assuming now Singapore is 5.704 million now
Assuming now Singapore is 50% of the Singaporean volunteer to take vaccine.. that' s 2.8m.. imagine 1 injection set cost about $50 bucks.... 150million revenue spread across 2021 beyond.
I am not encouraged to buy or sell. But just 2 cents here. Look at the function of the base number...
Even the CEO and director acquire more shares.. this pie.. seems to be solo eater RM.
Raffles Medical Group
On Feb 22, Raffles Medical Group executive chairman and co-founder Loo Choon Yong acquired 1.5 million shares of the private healthcare provider for a consideration of S$1,534,050.
At S$1.02 per share, this increased Dr Loo' s total interest in Raffles Medical Group from 52.31 per cent to 51.39 per cent.
Also on Feb 22, non-independent director Olivier Lim Tse Ghow acquired 134,000 shares for a consideration of S$137,350, at S$1.03 per share.
Prior to the Feb 22 market open, Raffles Medical Group reported revenue growth of 8.8 per cent to S$568.2 million for its FY20 (ended Dec 31), in spite of a challenging market environment as a result of the global Covid-19 pandemic.
With the results, Dr Loo paid tribute to the frontline workers and members of the group, noting that each day they go above, and beyond, to deliver on the group' s promise to its patients and corporate clients, as their trusted partner for health.
Dr Loo added that the resilience, dedication and agility of the group' s workforce, coupled with the strategic investments and austere planning have allowed it to emerge stronger amid this pandemic, with a healthy performance to give back to its shareholders and staff who have contributed.
gonna makan all 1.12.....
div 2ct coming.......
halleluyah ( Date: 01-Mar-2021 09:03) Posted:
|
cheong arhhh.......
Once Guang Dong & Shanghai turns profitable. S$3/- (S$1 x 3) will be within sight. Now just collect dividends:)
Any possible to reach $1.5
Just love how RM share price is gg to overtake Medtec:)
tis morning Phillips upgrade to accumulate wth tp 1.18.....
halleluyah ( Date: 26-Feb-2021 09:16) Posted:
| all casualities jeep tis raffles hosp....jia yu babe....1.20.... |
|
